Podcast: Rare Disease Day: FDA guidance allowing advancement
It’s been a busy year for rare disease developers, with the US Food and Drug Administration (FDA) releasing several new…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Gene editing takes centre stage in FDA’s new rare disease approval pathway
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway”, a new…
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to…
-
JPM26: BioNTech gears up for multiproduct oncology status by 2030
BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines.…
-
JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership
Eli Lilly and NVIDIA will establish a new artificial intelligence (AI) co-innovation lab, as the companies look to use each…
-
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and…
-
Genmab shelves Phase III lung cancer candidate
Genmab has discontinued development of acasunlimab, a bispecific antibody that was in mid and late-stage trials for solid tumours, including…
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its…
-
FDA unveils new pathway to usher bespoke therapies to market
The US Food and Drug Administration (FDA) has created a new pathway to bring personalised therapies to market that can…